Siltanen has written about how Herantis has been selected as a recipient of 8 million euros in funding from the Horizon Europe 2025 program. 
The news is very positive, as this non-dilutive funding covers a significant portion of the Phase II clinical trial for the HER-096 drug candidate, the total costs of which we estimate at 15–20 MEUR. The funding decision strengthens the company’s financial position and substantially reduces the downward pressure on the share price caused by a large dilutive share issue. We will update our forecasts to account for the new funding as well as the previous 4.2 MEUR share issue no later than in connection with the H2’25 report.